HC Wainwright Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $90.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 6.26% from the stock’s previous close. […]

Related Keywords

Sarah Kathryn Rouan ,Greg Zante ,Raymond James ,Stifel Nicolaus ,Jefferies Financial Group ,Therapeutics Inc ,Us Bancorp ,Cetera Advisor Networks ,Securities Exchange Commission ,Wetzel Investment Advisors Inc ,Retirement Group ,Viking Therapeutics ,Get Free Report ,Financial Group ,Exchange Commission ,Director Sarah Kathryn Rouan ,Advisor Networks ,Investment Advisors ,Gate Manager ,Viking Therapeutics Daily ,